ENHERTU® Granted Two Breakthrough Therapy Designations

Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colorectal cancer



ENHERTU has now been granted...

Related Keywords

United States , Japan , Israel , American , America , Susan Galbraith , Van Cutsem , Daiichi Sankyo , Ken Takeshita , National Cancer Institute , Drug Administration , Daiichi Sankyo Inc , Astrazeneca , Clinical Development Program , American Society Of Clinical Oncology , Nasdaq , Breakthrough Therapy Designations , Clinical Oncology , Annual Meeting , Cancers Symposium , Global Head , Executive Vice President , Lung Disease , Breast Cancer , Metastatic Gastric Cancer , Absolute Neutrophil Count , Positive Metastatic Breast , Low Metastatic Breast , Reproductive Potential , Hepatic Impairment , Prescribing Information , Accessed August , Enhertu Marks First Targeted Therapy , Mutant Lung , Markets ,